estrogen therapy (ET)
“Ghrelin and Leptin Changes in Serum of Postmenopausal Osteoporotic Iraqi Women after Three Months Oral Estrogen Therapy” by Elaf Mahmood Shihab, Mustafa G. Alabbassi, Khudair Z. AL-Bedri, Inas Taha Ahmad, Iraq.
... of estrogen reduces the somatostatin inhibitory drive on growth hormone secretion, as reported by relevant pilot studies, in accordance with finding that central effect of ghrelin is at least partially mediated ...
5
Fibrinogen storage disease without hypofibrinogenemia associated with estrogen therapy
... thrombin time were also within normal limits. The patient had no history of prolonged bleeding episodes, menorrhagia, or epistaxis. Since infectious, auto-immune or metabolic diseases were excluded, a drug effect was ...
5
Postmenopausal vaginal atrophy: evaluation of treatment with local estrogen therapy
... To be eligible for study participation, women were required to be US residents $18 years of age, menopausal (ie, not presenting with a spontaneous menstrual period for $1 year, or having had a double oophorectomy) and in ...
8
Overcoming resistance and barriers to the use of local estrogen therapy for the treatment of vaginal atrophy
... Local estrogen therapy is effective and safe for treatment of vaginal atrophy; however, barriers to treatment (eg, patient reluctance to discuss the condition, misinformation, incomplete understanding of ...
7
Barriers to effective treatment of vaginal atrophy with local estrogen therapy
... local estrogen therapy to prime the vaginal epithelium and produce noticeable results (eg, relief of vaginal dryness, irritation, itching, and pain on ...local estrogen therapy should be ...
6
The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy
... In support of antiarrhythmic effects of E2, Philp et al. ex- amined the effect of E2 on ischemia-induced cardiac ar- rhythmias and found that administration of E2 before coronary artery ligation exhibited ...
16
Hormone therapy and ovarian cancer: incidence and survival.
... cohort study, Lacey et al. detected a significantly increased risk of ovarian cancer in women who had used estrogen therapy for 10-19 years (HR=1.8, 95% CI: 1.1-3.0) or more than 20 years (HR=3.2, ...
23
ERβ and ApoE isoforms interact to regulate BDNF–5-HT2A signaling and synaptic function in the female brain
... between estrogen signaling and ApoE isoforms in the regulation of neural activities in the central nervous system [48, ...that estrogen therapy (ET) was associated with lesser cogni- tive ...
10
Nutrigenomic effects of edible bird’s nest on insulin signaling in ovariectomized rats
... rats. Estrogen therapy, on the other hand, was able to improve the lipid profile and OGTT, SOD, and MDA levels, and was even associated with some transcriptional changes in hepatic insulin signaling genes ...
11
Management of osteoporosis and menopausal symptoms: focus on bazedoxifene/conjugated estrogen combination
... of estrogen production in women during menopause results in a state of estrogen deficiency which has been associated with multiple problems, including vasomotor symptoms, symptoms of vulvovaginal atrophy, ...
11
Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case control study
... oral estrogen or local estrogen ...oral estrogen is noteworthy, and tentatively important with regard to the biolog- ical mechanisms of breast ...hormone therapy are differen- tially ...
13
Androgens and the breast
... against estrogen-induced mammary ...to estrogen therapy in ovariectomized rhesus monkeys significantly inhibits HT-induced mammary epithelial proliferation [3] (Figure ...epithelial estrogen ...
9
The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women
... of estrogen therapy sig- nificantly reduced mean LH and FSH levels to the same de- gree after 24 ...oral estrogen than during transder- mal estrogen therapy, and also higher than before ...
7
Current treatment options for postmenopausal vaginal atrophy
... of estrogen deficiency can be carried out with hormonal preparations with systemic and local action, as well as with preparations of plant ...pharmacological estrogen preparations sufficiently and quickly ...
9
Download Download PDF
... to therapy as marker will show the effect of treatment much faster ( - months) than bone density measurements which usually require - years of an intervention to register a significant change ...
5
<p>Ospemifene in the Management of Vulvar and Vaginal Atrophy: Focus on the Assessment of Patient Acceptability and Ease of Use</p>
... Recently, ospemifene, a new non-hormonal drug, was approved for the treatment of VVA symptoms. Ospemifene is a third-generation selective estrogen receptor modulator (SERM), that is administered orally at the dose ...
8
“Role of Aromatase and Anastrozole in Cancer Treatment” by Salam A. Mohammed, Firas Hassan, Anil K. Philip, Mays Abd-Allateef, Emad Yousif, Sultanate of Oman.
... as estrogen synthesize, is an enzyme chargeable for a key step in the synthesis of ...of estrogen in postmenopausal women) 24 ...of estrogen hormone synthesis from androgens specifically transforms ...
6
Medicinal Plants for the Treatment of Postmenopausal Osteoporosis
... Sohair et all reported the Cicerarithenium extract activates OPG synthesis and reduced RANKL expression in osteoblast , producing an increase of the OPG / RANKL ratio and slow down the process of osteoclast ...
16
Hormone Replacement Therapy: Would it be Possible to Replicate a Functional Ovary?
... Anti-Müllerian hormone (AMH also called Müllerian inhibiting substance (MIS)) is secreted in the ovary by the granulosa cells of preantral and small antral follicles [111]. It regulates the follicular development in an ...
19
Estrogen monotherapy and combined estrogen progestogen replacement therapy attenuate aortic accumulation of cholesterol in ovariectomized cholesterol fed rabbits
... Cardiovascular disease is currently the leading cause of death among women in the United States. To investigate the effect of postmenopausal hormone therapy on atherogenesis, we studied 75 cholesterol-fed female ...
7